Prosecution Insights
Prosecution Insights
17 pending office actions • 8 art units • 16 examiners • 0 of 17 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 17 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 17 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (35%) |
| §112 only | 4 (24%) |
| Double-patenting only | 1 (6%) |
| No statute on record | 6 (35%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 2 | 58.7% | +45.4% |
| FAY, ZOHREH ALEMZADEH | 1 | 51.8% | -6.7% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.9% |
| CHONG, YONG SOO | 1 | 43.7% | +41.6% |
| MARTINEZ, TARA L | 1 | 62.7% | +64.6% |
| CANELLA, KAREN A | 1 | 62.6% | +32.9% |
| LANDSMAN, ROBERT S | 1 | 81.3% | +12.9% |
| LIEB, JEANETTE M | 1 | 80.0% | +16.7% |
| KATAKAM, SUDHAKAR | 1 | 75.0% | +23.0% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031940 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | LANDSMAN, ROBERT S | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18250150 | NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF | CANELLA, KAREN A | 93d overdue |
| 18031958 | USE OF TRIGONAL AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS IN TREATMENT OF SEQUELAE FOLLOWING RESPIRATORY INFECTIOUS DISEASES | LIEB, JEANETTE M | 56d overdue |
| 18549622 | BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS | CHONG, YONG SOO | 32d overdue |
| 18028420 | THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF | HUYNH, PHUONG N | 3d overdue |
| 18031940 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | LANDSMAN, ROBERT S | 6d |
| 17788488 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF | SABILA, MERCY HELLEN | 12d |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 22d |
| 18032076 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS | KATAKAM, SUDHAKAR | 26d |
| Art Unit | Apps |
|---|---|
| 1654 | 6 |
| 1658 | 4 |
| 1641 | 2 |
| 1617 | 1 |
| 1629 | 1 |
| 1623 | 1 |
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576610 | ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 26d | Pending | Jan 04, 2024 |
| 18251827 | PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR | WEDDINGTON, KEVIN E | 1629 | §103 | Non-Final OA | 13d | Pending | Dec 12, 2023 |
| 18549622 | BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS | CHONG, YONG SOO | 1623 | §103 | Non-Final OA | 32d overdue | Pending | Sep 08, 2023 |
| 18269134 | COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME | MARTINEZ, TARA L | 1654 | DP | Non-Final OA | 84d | Pending | Jun 22, 2023 |
| 18250150 | NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF | CANELLA, KAREN A | 1643 | §112 | Non-Final OA | 93d overdue | Pending | Apr 21, 2023 |
| 18031940 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | 6d | Pending | Apr 14, 2023 |
| 18031958 | USE OF TRIGONAL AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS IN TREATMENT OF SEQUELAE FOLLOWING RESPIRATORY INFECTIOUS DISEASES | LIEB, JEANETTE M | 1654 | Other | Non-Final OA | 56d overdue | Pending | Apr 14, 2023 |
| 18032076 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS | KATAKAM, SUDHAKAR | 1658 | §112 | Final Rejection | 26d | Pending | Apr 14, 2023 |
| 18028420 | THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | 3d overdue | Pending | Mar 24, 2023 |
| 17915976 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME | BRADLEY, CHRISTINA | 1654 | §103 | Non-Final OA | 44d overdue | Pending | Sep 29, 2022 |
| 17880358 | IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN | DAHLE, CHUN WU | 1641 | Other | Final Rejection | 46d overdue | Pending | Aug 03, 2022 |
| 17788488 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF | SABILA, MERCY HELLEN | 1654 | §103 | Non-Final OA | 12d | Pending | Jun 23, 2022 |
| 17839053 | METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOGULIN FC FRAGMENT LINKAGE | REYNOLDS, FRED H | 1658 | §103 | Final Rejection | 98d overdue | Pending | Jun 13, 2022 |
| 17766137 | COMPOSITION COMPRISING GLUCAGON AND GLP-1 AND GIP RECEPTOR DUAL AGONIST AND THERAPEUTIC USE OF SAME | HELLMAN, KRISTINA M | 1654 | Other | Final Rejection | 16d | Pending | Apr 01, 2022 |
| 17700055 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | FISCHER, JOSEPH | 1658 | Other | Non-Final OA | 9d overdue | Pending | Mar 21, 2022 |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 1654 | Other | Final Rejection | 22d | Pending | Jun 21, 2021 |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | Other | Final Rejection | 22d | Pending | Apr 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial